School of Biology & Basic Medical Science, Soochow University, Suzhou, 215123, China.
National Engineering Laboratory for Modern Silk, Soochow University, Suzhou, 215123, China.
Sci Rep. 2018 May 8;8(1):7268. doi: 10.1038/s41598-018-25677-1.
Bombyx mori cypovirus (BmCPV), a member of the Reoviridae, specifically infects silkworms and causes extensive economic losses to the sericulture industry. To date, the entry mechanism of BmCPV into cells is unclear. Here we used electron microscopy to study the route of entry of BmCPV into cells, and the results demonstrated that the entry of BmCPV into BmN cells was mediated by endocytosis. Blocking the entry pathway with four endocytosis inhibitors, including dansylcadaverine, chlorpromazine, genistein, and PP2, significantly decreased the infectivity of BmCPV. This indicates that BmCPV enters BmN cells via endocytosis, and that clathrin-mediated sorting is the predominant entry method. After the relative expression levels of clathrin heavy chain (clathrin, GenBank accession No. NM_001142971.1) and the adaptor protein complex-1 gamma subunit AP-1 (AP-1, GenBank accession No. JQ824201.1), which are involved in clathrin-mediated endocytosis, were inhibited by RNA interference or abolishing the functions of clathrin and AP-1 with their corresponding antibodies, the infectivity of BmCPV was reduced significantly, which suggests that clathrin-mediated endocytosis contributed to the entry of BmCPV into cells. Our findings suggest that the clathrin-mediated endocytosis pathway is a candidate for the development of therapeutics for silkworm cytoplasmic polyhedrosis.
家蚕质型多角体病毒(BmCPV)是呼肠孤病毒科的一员,专门感染家蚕,给蚕业造成巨大经济损失。迄今为止,BmCPV 进入细胞的机制尚不清楚。本研究利用电子显微镜研究了 BmCPV 进入细胞的途径,结果表明 BmCPV 进入 BmN 细胞是通过内吞作用介导的。用四种内吞作用抑制剂(丹磺酰尸胺、氯丙嗪、染料木黄酮和 PP2)阻断进入途径,显著降低了 BmCPV 的感染性。这表明 BmCPV 通过内吞作用进入 BmN 细胞,网格蛋白介导的分选是主要的进入方式。用 RNA 干扰或相应的抗体抑制参与网格蛋白介导的内吞作用的网格蛋白重链(网格蛋白,GenBank 登录号 NM_001142971.1)和衔接蛋白复合物 1 伽马亚基(AP-1,GenBank 登录号 JQ824201.1)的相对表达水平后,BmCPV 的感染性显著降低,表明网格蛋白介导的内吞作用有助于 BmCPV 进入细胞。我们的研究结果表明,网格蛋白介导的内吞作用途径是开发蚕细胞质多角体病治疗药物的候选途径。